Rural Health
Resources by Topic: Illicit drug use
Telemedicine Buprenorphine Access For Incarcerated People: Lessons Learned From Maryland's Rural Jails
Explores the lessons learned form implementing a telemedicine-based buprenorphine treatment for opioid use disorder in rural Maryland jails. Highlights the challenges and opportunities expanding, establishing, and implementing buprenorphine treatment via tele-medicine. Draws conclusions for future interventions.
Author(s): Max Spaderna, Annabelle M. Belcher, Chris Welsh, et al.
Citation: Health Affairs, 44(9), 1131-1137
Date: 09/2025
view details
Explores the lessons learned form implementing a telemedicine-based buprenorphine treatment for opioid use disorder in rural Maryland jails. Highlights the challenges and opportunities expanding, establishing, and implementing buprenorphine treatment via tele-medicine. Draws conclusions for future interventions.
Author(s): Max Spaderna, Annabelle M. Belcher, Chris Welsh, et al.
Citation: Health Affairs, 44(9), 1131-1137
Date: 09/2025
view details
Modeling the Impact of Changing Drug Markets and Structural Determinants on HCV and/or HIV Transmission Among People Who Inject Drugs in the United States: A Rural and Urban Comparison
Details a study exploring the impact of changing patterns of drug use in rural and urban areas are affecting the rates of hepatitis C virus (HCV) and HIV incidence among people who inject drugs (PWID). Compares rates of infection and drug use in San Diego, CA and rural Central and Northern, WI.
Author(s): Natasha K. Martin, Daniela Abramovitz, William H. Eger, et al.
Citation: International Journal of Drug Policy, 143, 104925
Date: 09/2025
view details
Details a study exploring the impact of changing patterns of drug use in rural and urban areas are affecting the rates of hepatitis C virus (HCV) and HIV incidence among people who inject drugs (PWID). Compares rates of infection and drug use in San Diego, CA and rural Central and Northern, WI.
Author(s): Natasha K. Martin, Daniela Abramovitz, William H. Eger, et al.
Citation: International Journal of Drug Policy, 143, 104925
Date: 09/2025
view details
Treatment Initiations and Opioid Overdoses among Recently Incarcerated People after Adoption of the Take-Home Methadone Policy
Explores the effect flexible methadone policies implemented during the COVID-19 pandemic had on opioid overdoses and treatment initiation and uptake among incarcerated people upon release. Highlights the effect this policy had on rural areas and communities that lack access to opioid treatment.
Author(s): Benjamin A. Barsky, Shapei Yan, Meredith B. Rosenthal
Citation: Drug and Alcohol Dependence, 274, 112775
Date: 09/2025
view details
Explores the effect flexible methadone policies implemented during the COVID-19 pandemic had on opioid overdoses and treatment initiation and uptake among incarcerated people upon release. Highlights the effect this policy had on rural areas and communities that lack access to opioid treatment.
Author(s): Benjamin A. Barsky, Shapei Yan, Meredith B. Rosenthal
Citation: Drug and Alcohol Dependence, 274, 112775
Date: 09/2025
view details
Pharmacy Barriers to Receiving Buprenorphine Among Patients Undergoing Telemedicine Addiction Treatment
Presents a study exploring pharmacy-level barriers experienced by patients with opioid use disorder who are receiving treatment via telemedicine. Discusses barriers that lead to missed doses or inaccessible prescriptions. Breaks down data by health and demographic characteristics, such as age, education, and insurance type, among others, and whether the patient lived in a rural or nonrural area.
Author(s): Lauren E. Hendy, Lucas G. Hill, Amanda Olguin, et al.
Citation: JAMA Network Open, 8(8), e2527418
Date: 08/2025
view details
Presents a study exploring pharmacy-level barriers experienced by patients with opioid use disorder who are receiving treatment via telemedicine. Discusses barriers that lead to missed doses or inaccessible prescriptions. Breaks down data by health and demographic characteristics, such as age, education, and insurance type, among others, and whether the patient lived in a rural or nonrural area.
Author(s): Lauren E. Hendy, Lucas G. Hill, Amanda Olguin, et al.
Citation: JAMA Network Open, 8(8), e2527418
Date: 08/2025
view details
Opportunities for Employers to Address the Opioid Epidemic: Results from a National Survey
Surveys 1,010 employees to learn their perspective on the Recovery-Ready Workplace (RRW) framework, a federally created opioid intervention for employers. Evaluates the implementation of the 4 areas addressed by RRW, noting areas for improvement related to Narcan access, stigma, and work arrangements that accommodate treatment.
Author(s): Gillian K. SteelFisher, Brian C. Castrucci, Mary G. Findling, et al.
Citation: Health Affairs Scholar, 3(8)
Date: 08/2025
view details
Surveys 1,010 employees to learn their perspective on the Recovery-Ready Workplace (RRW) framework, a federally created opioid intervention for employers. Evaluates the implementation of the 4 areas addressed by RRW, noting areas for improvement related to Narcan access, stigma, and work arrangements that accommodate treatment.
Author(s): Gillian K. SteelFisher, Brian C. Castrucci, Mary G. Findling, et al.
Citation: Health Affairs Scholar, 3(8)
Date: 08/2025
view details
Drug Overdose Deaths in Kentucky, 2019–2024: Are We Back to Pre-COVID-19 Levels?
Examines drug overdose deaths in Kentucky and the impact of COVID-19 on mortality rates. Utilizes 2019-2024 Kentucky Office of Vital Statistics data to analyze overdose mortality rates according to year, demographics, contributing drugs, and metro versus nonmetro location.
Author(s): Aaron P. Smith, Juan Lang, Carmen Canedo, et al.
Citation: Injury Epidemiology, 12, 51
Date: 08/2025
view details
Examines drug overdose deaths in Kentucky and the impact of COVID-19 on mortality rates. Utilizes 2019-2024 Kentucky Office of Vital Statistics data to analyze overdose mortality rates according to year, demographics, contributing drugs, and metro versus nonmetro location.
Author(s): Aaron P. Smith, Juan Lang, Carmen Canedo, et al.
Citation: Injury Epidemiology, 12, 51
Date: 08/2025
view details
Prescribed Medications for Patients with Amphetamine-Type Stimulant Use Disorder Seen in Rural-Serving Pacific Northwest Primary Care Clinics
Examines the frequency in which patients living in the rural Pacific Northwest with amphetamine-type stimulant use disorder (AT-StUD) received medications for AT-StUD in primary care clinics. Utilizes 2017-2021 electronic health record (EHR) data to analyze patients who have received prescriptions according to demographics, mental health status, and health behaviors.
Author(s): Megan J. Yerton, Connor J. McCabe, Matthew D. Iles-Shih, Judith I. Tsui, Kevin A. Hallgren
Citation: Addiction Science & Clinical Practice, 20, 67
Date: 08/2025
view details
Examines the frequency in which patients living in the rural Pacific Northwest with amphetamine-type stimulant use disorder (AT-StUD) received medications for AT-StUD in primary care clinics. Utilizes 2017-2021 electronic health record (EHR) data to analyze patients who have received prescriptions according to demographics, mental health status, and health behaviors.
Author(s): Megan J. Yerton, Connor J. McCabe, Matthew D. Iles-Shih, Judith I. Tsui, Kevin A. Hallgren
Citation: Addiction Science & Clinical Practice, 20, 67
Date: 08/2025
view details
Examining Geographic Disparities in Access to No-Cost Naloxone in North Carolina: A Cross-Sectional Survey of Naloxone Distribution Programs
Presents a study exploring the geographic distribution of no-cost naloxone in North Carolina. Bases findings on a survey of naloxone distributors in the state and breaks down data by user demographics and distributor type.
Author(s): Grace Marley, Caroline Shubel, Carolyn T. Thorpe, et al.
Citation: Journal of Rural Health, 41(3), e70069
Date: 08/2025
view details
Presents a study exploring the geographic distribution of no-cost naloxone in North Carolina. Bases findings on a survey of naloxone distributors in the state and breaks down data by user demographics and distributor type.
Author(s): Grace Marley, Caroline Shubel, Carolyn T. Thorpe, et al.
Citation: Journal of Rural Health, 41(3), e70069
Date: 08/2025
view details
Illegally Made Fentanyl Use in the United States: 2022 and 2023
Report highlights findings from the 2022 and 2023 National Survey on Drug Use and Health (NSDUH) on the use of illegally made fentanyl across the U.S. Explores co-usage with other drugs, emergency room visits/hospitalizations, and breaks down user characteristics by age, poverty level, and rurality, among other measures.
Citation: NSDUH Data Brief, 2(2)
Date: 07/2025
Sponsoring organizations: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration
view details
Report highlights findings from the 2022 and 2023 National Survey on Drug Use and Health (NSDUH) on the use of illegally made fentanyl across the U.S. Explores co-usage with other drugs, emergency room visits/hospitalizations, and breaks down user characteristics by age, poverty level, and rurality, among other measures.
Citation: NSDUH Data Brief, 2(2)
Date: 07/2025
Sponsoring organizations: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration
view details
Evaluation of the Maternal Opioid Misuse (MOM) Model: Fourth Annual Report (Implementation Year 3)
Provides an overview of the Maternal Opioid Misuse Model, which provides evidence-based integrated care and care coordination for pregnant and postpartum Medicaid beneficiaries with opioid use disorder (OUD). Describes activities MOM Model awardees undertook during the MOM Model's second implementation year, July 1, 2023–June 30, 2024, and summarizes qualitative and beneficiary-level process data findings by state awardee. Discusses barriers pregnant and postpartum women with OUD face in accessing high-quality, continuous care, specifically in rural areas.
Additional links: Findings at a Glance
Date: 06/2025
Sponsoring organizations: Centers for Medicare and Medicaid Services, Westat
view details
Provides an overview of the Maternal Opioid Misuse Model, which provides evidence-based integrated care and care coordination for pregnant and postpartum Medicaid beneficiaries with opioid use disorder (OUD). Describes activities MOM Model awardees undertook during the MOM Model's second implementation year, July 1, 2023–June 30, 2024, and summarizes qualitative and beneficiary-level process data findings by state awardee. Discusses barriers pregnant and postpartum women with OUD face in accessing high-quality, continuous care, specifically in rural areas.
Additional links: Findings at a Glance
Date: 06/2025
Sponsoring organizations: Centers for Medicare and Medicaid Services, Westat
view details